Jeremy Abramson, MD, MMSc

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Genentech
    Topic:
    lymphoma
    Date added:
    01/16/2024
    Date updated:
    01/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    BMS
    Topic:
    lymphoma
    Date added:
    01/16/2024
    Date updated:
    01/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Gilead
    Topic:
    lymphoma
    Date added:
    01/16/2024
    Date updated:
    01/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Seagen
    Topic:
    lymphoma
    Date added:
    01/16/2024
    Date updated:
    01/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Interius
    Topic:
    lymphoma
    Date added:
    01/16/2024
    Date updated:
    01/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    AbbVie
    Topic:
    lymphoma
    Date added:
    01/16/2024
    Date updated:
    01/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    BeiGene
    Topic:
    lymphoma
    Date added:
    01/16/2024
    Date updated:
    01/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Lilly
    Topic:
    lymphoma
    Date added:
    01/16/2024
    Date updated:
    01/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Cellectar
    Topic:
    lymphoma
    Date added:
    01/16/2024
    Date updated:
    01/16/2024
    Relationship end date:
    02/17/2023
Return to Upstate New York Hematology & Hematologic Oncology Conference: Updates from the 65th ASH Annual Meeting